Second European Country To Commence Cerepro(R) Treatment On Named Patient Basis, England

Ark Therapeutics Group plc (AKT:LSE) announces that Named Patient Supply (NPS) for Cerepro® (sitimagene ceradenovec) has been approved in Finland by the National Agency for Medicines (NAM). The approval follows an application made by a neuro-surgeon in Finland for the use of Cerepro®. Finland is the second country to approve NPS, the first being France which approved NPS in February 2009.

More: continued here

Filed under: Cancer on May 18th, 2009